<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37033033</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.</ArticleTitle><Pagination><StartPage>1098419</StartPage><MedlinePgn>1098419</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1098419</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2023.1098419</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Detection of poliovirus transmission and ongoing oral poliovirus vaccine (OPV) use continue to delay poliomyelitis eradication. In 2016, the Global Polio Eradication Initiative (GPEI) coordinated global cessation of type 2 OPV (OPV2) for preventive immunization and limited its use to emergency outbreak response. In 2019, GPEI partners requested restart of some Sabin OPV2 production and also accelerated the development of a genetically modified novel OPV2 vaccine (nOPV2) that promised greater genetic stability than monovalent Sabin OPV2 (mOPV2).</AbstractText><AbstractText Label="METHODS">We reviewed integrated risk, economic, and global poliovirus transmission modeling performed before OPV2 cessation, which recommended multiple risk management strategies to increase the chances of successfully ending all transmission of type 2 live polioviruses. Following OPV2 cessation, strategies implemented by countries and the GPEI deviated from model recommended risk management strategies. Complementing other modeling that explores prospective outbreak response options for improving outcomes for the current polio endgame trajectory, in this study we roll back the clock to 2017 and explore counterfactual trajectories that the polio endgame could have followed if GPEI had: (1) managed risks differently after OPV2 cessation and/or (2) developed nOPV2 before and used it exclusively for outbreak response after OPV2 cessation.</AbstractText><AbstractText Label="RESULTS">The implementation of the 2016 model-based recommended outbreak response strategies could have ended (and could still substantially improve the probability of ending) type 2 poliovirus transmission. Outbreak response performance observed since 2016 would not have been expected to achieve OPV2 cessation with high confidence, even with the availability of nOPV2 prior to the 2016 OPV2 cessation.</AbstractText><AbstractText Label="DISCUSSION">As implemented, the 2016 OPV2 cessation failed to stop type 2 transmission. While nOPV2 offers benefits of lower risk of seeding additional outbreaks, its reduced secondary spread relative to mOPV2 may imply relatively higher coverage needed for nOPV2 than mOPV2 to stop outbreaks.</AbstractText><CopyrightInformation>Copyright © 2023 Thompson, Kalkowska and Badizadegan.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalkowska</LastName><ForeName>Dominika A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badizadegan</LastName><ForeName>Kamran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cessation</Keyword><Keyword MajorTopicYN="N">dynamic modeling</Keyword><Keyword MajorTopicYN="N">eradication</Keyword><Keyword MajorTopicYN="N">immunization</Keyword><Keyword MajorTopicYN="N">oral poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">outbreak response</Keyword><Keyword MajorTopicYN="N">polio</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>10</Day><Hour>3</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37033033</ArticleId><ArticleId IdType="pmc">PMC10080024</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2023.1098419</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thompson KM, Segui-Gomez M, Graham JD. Validating analytical judgments: the case of the airbag's lifesaving effectiveness. Reliability Eng Syst Safety. (1999) 66:57–68. 10.1016/S0951-8320(99)00019-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0951-8320(99)00019-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofonea MT, Alizon S. Anticipating COVID-19 intensive care unit capacity strain: A look back at epidemiological projections in France. Anaesth Crit Care Pain Med. (2021) 40:100943. 10.1016/j.accpm.2021.100943</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.accpm.2021.100943</ArticleId><ArticleId IdType="pmc">PMC8407772</ArticleId><ArticleId IdType="pubmed">34479681</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000-2019 to support global polio eradication. Expert Rev Vaccines. (2020) 19:661–86. 10.1080/14760584.2020.1791093</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2020.1791093</ArticleId><ArticleId IdType="pmc">PMC7497282</ArticleId><ArticleId IdType="pubmed">32741232</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA. Reflections on modeling poliovirus transmission and the polio eradication endgame. Risk Anal. (2021) 41:229–47. 10.1111/risa.13484</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13484</ArticleId><ArticleId IdType="pmc">PMC7983882</ArticleId><ArticleId IdType="pubmed">32339327</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Global Polio Eradication Initiative. Circulating Vaccine-Derived Poliovirus.  (2023). Available online at: https://polioeradication.org/wp-content/uploads/2023/02/weekly-polio-analyses-cVDPV-20230221.pdf (accesssed February 24, 2023).</Citation></Reference><Reference><Citation>World Health Assembly . Global Eradication of Poliomyelitis by the Year 2000 (resolution 41.28). Geneva: World Health Organization; (1988).</Citation></Reference><Reference><Citation>World Health Organization . Global Eradication of Poliomyelitis: Report of the Second Meeting of the Global Technical Consultative Group (TCG). Geneva: Department of Vaccines and Biologicals, World Health Organization; (1997).</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, et al. . Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. (2006) 26:1471–505. 10.1111/j.1539-6924.2006.00827.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1539-6924.2006.00827.x</ArticleId><ArticleId IdType="pubmed">17184393</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, et al. . Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal. (2013) 33:680–702. 10.1111/risa.12022</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.12022</ArticleId><ArticleId IdType="pmc">PMC7890645</ArticleId><ArticleId IdType="pubmed">23470192</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol. (1999) 150:1001–21. 10.1093/oxfordjournals.aje.a009924</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a009924</ArticleId><ArticleId IdType="pubmed">10568615</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Assembly . Poliomyelitis: Mechanism for Management of Potential Risks to Eradication (resolution 61.1). Geneva: WHO; (2008).</Citation></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Expert Rev Vaccines. (2012) 11:449–59. 10.1586/erv.11.195</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.11.195</ArticleId><ArticleId IdType="pubmed">22551030</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. BMC Infect Dis. (2015) 15:376. 10.1186/s12879-015-1116-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1116-4</ArticleId><ArticleId IdType="pmc">PMC4574692</ArticleId><ArticleId IdType="pubmed">26382234</ArticleId></ArticleIdList></Reference><Reference><Citation>Badizadegan K, Kalkowska DA, Thompson KM. Polio by the numbers-a global perspective. J Infect Dis. (2022) 226:1309–18. 10.1093/infdis/jiac130</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac130</ArticleId><ArticleId IdType="pmc">PMC9556648</ArticleId><ArticleId IdType="pubmed">35415741</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Global Polio Eradication Initiative. Polio Eradication and Endgame Strategic Plan  (2013–2018). (2013). Available online at: http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf (accesssed February 24, 2023).</Citation></Reference><Reference><Citation>Thompson KM, Pallansch MA, Tebbens RJ, Wassilak SG, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal. (2013) 33:647–63. 10.1111/j.1539-6924.2012.01891.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1539-6924.2012.01891.x</ArticleId><ArticleId IdType="pmc">PMC7896539</ArticleId><ArticleId IdType="pubmed">22985171</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. (2014) 210:S475–84. 10.1093/infdis/jit845</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit845</ArticleId><ArticleId IdType="pubmed">25316870</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis. (2014) 210:S485–97. 10.1093/infdis/jit838</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit838</ArticleId><ArticleId IdType="pubmed">25316871</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Meeting of the strategic advisory group of experts on immunization, October 2014—conclusions and recommendations. Weekly Epidemiol Record. (2014) 89:561–76.</Citation><ArticleIdList><ArticleId IdType="pubmed">25513671</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S, Lewis I, et al. . Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine—worldwide, 2016. MMWR. (2016) 65:934–8. 10.15585/mmwr.mm6535a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6535a3</ArticleId><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infecti Dis. (2016) 16:137. 10.1186/s12879-016-1465-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-016-1465-7</ArticleId><ArticleId IdType="pmc">PMC4806487</ArticleId><ArticleId IdType="pubmed">27009272</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. BMC Infect Dis. (2015) 15:390. 10.1186/s12879-015-1114-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1114-6</ArticleId><ArticleId IdType="pmc">PMC4582727</ArticleId><ArticleId IdType="pubmed">26404780</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013–2052. BMC Infect Dis. (2015) 15:389. 10.1186/s12879-015-1112-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1112-8</ArticleId><ArticleId IdType="pmc">PMC4582932</ArticleId><ArticleId IdType="pubmed">26404632</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis. (2015) 15:379. 10.1186/s12879-015-1115-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1115-5</ArticleId><ArticleId IdType="pmc">PMC4574619</ArticleId><ArticleId IdType="pubmed">26382043</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. Future Microbiol. (2016) 11:1549–61. 10.2217/fmb-2016-0126</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2016-0126</ArticleId><ArticleId IdType="pubmed">27831742</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Uncertainty and sensitivity analysis of cost assumptions for global long-term poliovirus risk management. J Vaccines Vacc. (2016) 7:339. 10.4172/2157-7560.1000339</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2157-7560.1000339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Wassilak SGF, Cochi SL, Pallansch MA, Thompson KM. Global transmission of live polioviruses: updated integrated dynamic modeling of the polio endgame. Risk Anal. (2021) 41:248–65. 10.1111/risa.13447</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13447</ArticleId><ArticleId IdType="pmc">PMC7787008</ArticleId><ArticleId IdType="pubmed">31960533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Cochi SL, Kovacs SD, Wassilak SGF, Thompson KM. Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart. Risk Anal. (2021) 41:320–8. 10.1111/risa.13555</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13555</ArticleId><ArticleId IdType="pmc">PMC7814395</ArticleId><ArticleId IdType="pubmed">32632925</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G, Peak C, Eisenhawer M, Kurji F, Mach O, Konz J, et al. . Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel oral polio vaccine type 2 (nOPV2) experience. Vaccine. (2022) S0264–410. 10.1016/j.vaccine.2022.02.050. [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.050.</ArticleId><ArticleId IdType="pmc">PMC10109087</ArticleId><ArticleId IdType="pubmed">35307230</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. 14th Meeting of the Global Commission for Certification of Poliomyelitis Eradication (GCC), Bali, Indonesia.  (2015). Available online at: http://polioeradication.org/wp-content/uploads/2016/07/1Report.pdf (accesssed February 24, 2023).</Citation></Reference><Reference><Citation>World Health Organization. Global Polio Eradication Initiative. Standard Operating Procedures: Responding to a Poliovirus Event or Outbreak: Part 1: General SOPs.  (2016). Available online at: https://s3.amazonaws.com/gpei-tk/reference_links/en/GPEI_SOPs.pdf (accesssed February 24, 2023).</Citation></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Lessons from globally-coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. J Infect Dis. (2017) 216:S168–S75. 10.1093/infdis/jix128</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix128</ArticleId><ArticleId IdType="pmc">PMC5853947</ArticleId><ArticleId IdType="pubmed">28838198</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: Insights from integrated modeling. Expert Rev Vaccines. (2017) 16:577–86. 10.1080/14760584.2017.1322514</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2017.1322514</ArticleId><ArticleId IdType="pubmed">28437234</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Lessons from the polio endgame: Overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission. J Infect Dis. (2017) 216:S176–S82. 10.1093/infdis/jix108</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix108</ArticleId><ArticleId IdType="pmc">PMC5853387</ArticleId><ArticleId IdType="pubmed">28838194</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines. (2018) 17:739–51. 10.1080/14760584.2018.1506333</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1506333</ArticleId><ArticleId IdType="pmc">PMC6168953</ArticleId><ArticleId IdType="pubmed">30056767</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt DT, Farag NH, Hadler SC, et al. . Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations. Risk Anal. (2018) 38:1701–17. 10.1111/risa.12962</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.12962</ArticleId><ArticleId IdType="pmc">PMC7879700</ArticleId><ArticleId IdType="pubmed">29314143</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use. Med Decis Making Policy Practice. (2017) 2:2381468317697002. 10.1177/2381468317697002</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2381468317697002</ArticleId><ArticleId IdType="pmc">PMC6124926</ArticleId><ArticleId IdType="pubmed">30288417</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Using integrated modeling to support the global eradication of vaccine-preventable diseases. System Dyn Rev. (2018) 34:78–120. 10.1002/sdr.1589</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sdr.1589</ArticleId><ArticleId IdType="pmc">PMC8455164</ArticleId><ArticleId IdType="pubmed">34552305</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Thompson KM. Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters. Epidemiol Infect. (2019) 147:e295. 10.1017/S095026881900181X</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S095026881900181X</ArticleId><ArticleId IdType="pmc">PMC6813650</ArticleId><ArticleId IdType="pubmed">31647050</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Kalkowska DA, Thompson KM. Poliovirus containment risks and their management. Future Virol. (2018) 13:617–28. 10.2217/fvl-2018-0079</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl-2018-0079</ArticleId><ArticleId IdType="pmc">PMC7885305</ArticleId><ArticleId IdType="pubmed">33598044</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). Expert Rev Vaccines. (2019) 18:725–36. 10.1080/14760584.2019.1635463</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2019.1635463</ArticleId><ArticleId IdType="pmc">PMC6816497</ArticleId><ArticleId IdType="pubmed">31248293</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, O'Reilly KM, Grassly NC, Edmunds WJ, Mach O, Santhana Gopala Krishnan R, et al. . Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. (2020) 368:401–5. 10.1126/science.aba1238</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aba1238</ArticleId><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Global Polio Eradication Initiative. Polio Eradication and Endgame Strategic Plan  (2019–2023). (2019). Available online at: https://polioeradication.org/wp-content/uploads/2019/06/english-polio-endgame-strategy.pdf (accesssed February 24, 2023).</Citation></Reference><Reference><Citation>World Health Organization . Global Polio Eradication Initiative. Strategy For The Response To Type 2 Circulating Vaccine-Derived Poliovirus 2020–2021: Addendum To The Polio Eradication And Endgame Strategy 2019–2023. Geneva: World Health Organization; (2020).</Citation></Reference><Reference><Citation>World Health Organization. Global Polio Eradication Initiative. Polio Eradication Strategy 2022–2026: Delivering on a Promise.  (2021). Available online at: https://polioeradication.org/wp-content/uploads/2021/06/polio-eradication-strategy-2022-2026-pre-publication-version-20210609.pdf (accesssed February 24, 2023).</Citation></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay AS, Konopka-Anstadt JL, Burns CC, et al. . Updated characterization of poliovirus outbreak response strategies for 2019–2029: impacts of the use of novel OPV2 strains. Risk Anal. (2021) 41:329–48. 10.1111/risa.13622</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13622</ArticleId><ArticleId IdType="pmc">PMC7887065</ArticleId><ArticleId IdType="pubmed">33174263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Voorman A, Pallansch MA, Wassilak SGF, Cochi SL, Badizadegan K, et al. . The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. Vaccine. (2021) S0264–410. 10.1016/j.vaccine.2021.04.026. [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.04.026.</ArticleId><ArticleId IdType="pmc">PMC10045205</ArticleId><ArticleId IdType="pubmed">33962838</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine. (2021) S0264–410. 10.1016/j.vaccine.2021.04.061. [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.04.061.</ArticleId><ArticleId IdType="pmc">PMC11027208</ArticleId><ArticleId IdType="pubmed">33994237</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Wassilak SGF, Pallansch MA, Burns CC, Wiesen E, Durry E, et al. . Outbreak response strategies with type 2-containing oral poliovirus vaccines. Vaccine. (2022) S0264–410. 10.1016/j.vaccine.2022.10.060. [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.10.060.</ArticleId><ArticleId IdType="pmc">PMC10284582</ArticleId><ArticleId IdType="pubmed">36402659</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka-Anstadt JL, Campagnoli R, Vincent A, Shaw J, Wei L, Wynn NT, et al. . Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. (2020) 5:26. 10.1038/s41541-020-0176-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-0176-7</ArticleId><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SGF, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. (2013) 33:703–49. 10.1111/risa.12044</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.12044</ArticleId><ArticleId IdType="pubmed">23521018</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas K, Procter SR, van Zandvoort K, Clark A, Funk S, Mengistu T, et al. . Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit-risk analysis of health benefits vs. excess risk of SARS-CoV-2 infection. Lancet Global Health. (2020) 8:e1264–e1272. 10.1016/S2214-109X(20)30308-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(20)30308-9</ArticleId><ArticleId IdType="pmc">PMC7367673</ArticleId><ArticleId IdType="pubmed">32687792</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J, Burns CC, Jorba J, Shulman LM, Macadam A, Klapsa D, et al. . Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under emergency use listing—worldwide, March–October 2021. MMWR Morb Mortal Wkly Rep. (2022) 71:786–90. 10.15585/mmwr.mm7124a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7124a2</ArticleId><ArticleId IdType="pubmed">35709073</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. BMC Infect Dis. (2015) 15:374. 10.1186/s12879-015-1113-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1113-7</ArticleId><ArticleId IdType="pmc">PMC4574397</ArticleId><ArticleId IdType="pubmed">26381878</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. This Week: Polio This Week as of 22 February 2023.  (2023). Available online at: https://polioeradication.org/polio-today/polio-now/this-week/ (accesssed February 24, 2023).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>